BREAKING
LIVE MARKETS
US📈 S&P 500$5,738.17▲ 0.41% METAL🥇 GOLD$2,658.40/oz▲ 0.52% ENERGY🛢️ BRENT$71.89/bbl▲ 0.68% CRYPTO₿ BTC$65,840.00▲ 1.85% IN🇮🇳 NIFTY 50₹26,178.95▲ 0.30% METAL🥈 SILVER$31.62/oz▲ 1.18% US💻 NASDAQ$18,179.59▲ 0.60% ENERGY🛢️ WTI CRUDE$68.18/bbl▲ 0.75% CRYPTOΞ ETH$2,664.20▲ 2.10% IN🇮🇳 SENSEX₹85,571.85▲ 0.28% US🏛️ DOW$42,313.00▲ 0.33% CRYPTO◎ SOL$156.40▲ 4.30% UK🇬🇧 FTSE 100£8,320.72▲ 0.43% CRYPTO⬡ BNB$598.20▲ 0.85% US📈 S&P 500$5,738.17▲ 0.41% METAL🥇 GOLD$2,658.40/oz▲ 0.52% ENERGY🛢️ BRENT$71.89/bbl▲ 0.68% CRYPTO₿ BTC$65,840.00▲ 1.85% IN🇮🇳 NIFTY 50₹26,178.95▲ 0.30% METAL🥈 SILVER$31.62/oz▲ 1.18% US💻 NASDAQ$18,179.59▲ 0.60% ENERGY🛢️ WTI CRUDE$68.18/bbl▲ 0.75% CRYPTOΞ ETH$2,664.20▲ 2.10% IN🇮🇳 SENSEX₹85,571.85▲ 0.28% US🏛️ DOW$42,313.00▲ 0.33% CRYPTO◎ SOL$156.40▲ 4.30% UK🇬🇧 FTSE 100£8,320.72▲ 0.43% CRYPTO⬡ BNB$598.20▲ 0.85%
Markets

Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Original Source: NewsData.io Business & Tech Wire

Comments (0)

No comments yet. Be the first to share your thoughts!

Leave a Comment

Your comment will appear after moderation. Max 2000 characters.